215 related articles for article (PubMed ID: 37598484)
1. Discovery of highly potent covalent SARS-CoV-2 3CL
Zhang FM; Huang T; Wang F; Zhang GS; Liu D; Dai J; Zhang JW; Li QH; Lin GQ; Gao D; Zhao J; Tian P
Eur J Med Chem; 2023 Nov; 260():115721. PubMed ID: 37598484
[TBL] [Abstract][Full Text] [Related]
2. Discovery of natural catechol derivatives as covalent SARS-CoV-2 3CL
Wang F; Liu D; Gao D; Yuan J; Zhao J; Yuan S; Cen Y; Lin GQ; Zhao J; Tian P
Int J Biol Macromol; 2024 Apr; 264(Pt 1):130377. PubMed ID: 38395279
[TBL] [Abstract][Full Text] [Related]
3. Discovery of Chlorofluoroacetamide-Based Covalent Inhibitors for Severe Acute Respiratory Syndrome Coronavirus 2 3CL Protease.
Hirose Y; Shindo N; Mori M; Onitsuka S; Isogai H; Hamada R; Hiramoto T; Ochi J; Takahashi D; Ueda T; Caaveiro JMM; Yoshida Y; Ohdo S; Matsunaga N; Toba S; Sasaki M; Orba Y; Sawa H; Sato A; Kawanishi E; Ojida A
J Med Chem; 2022 Oct; 65(20):13852-13865. PubMed ID: 36229406
[TBL] [Abstract][Full Text] [Related]
4. Discovery and Mechanism Study of SARS-CoV-2 3C-like Protease Inhibitors with a New Reactive Group.
Ren P; Li H; Nie T; Jian X; Yu C; Li J; Su H; Zhang X; Li S; Yang X; Peng C; Yin Y; Zhang L; Xu Y; Liu H; Bai F
J Med Chem; 2023 Sep; 66(17):12266-12283. PubMed ID: 37594952
[TBL] [Abstract][Full Text] [Related]
5. Discovery of 9,10-dihydrophenanthrene derivatives as SARS-CoV-2 3CL
Zhang JW; Xiong Y; Wang F; Zhang FM; Yang X; Lin GQ; Tian P; Ge G; Gao D
Eur J Med Chem; 2022 Jan; 228():114030. PubMed ID: 34883292
[TBL] [Abstract][Full Text] [Related]
6. Identification of pyrogallol as a warhead in design of covalent inhibitors for the SARS-CoV-2 3CL protease.
Su H; Yao S; Zhao W; Zhang Y; Liu J; Shao Q; Wang Q; Li M; Xie H; Shang W; Ke C; Feng L; Jiang X; Shen J; Xiao G; Jiang H; Zhang L; Ye Y; Xu Y
Nat Commun; 2021 Jun; 12(1):3623. PubMed ID: 34131140
[TBL] [Abstract][Full Text] [Related]
7. Discovery and mechanism of action of Thonzonium bromide from an FDA-approved drug library with potent and broad-spectrum inhibitory activity against main proteases of human coronaviruses.
Wang R; Zhai G; Zhu G; Wang M; Gong X; Zhang W; Ge G; Chen H; Chen L
Bioorg Chem; 2023 Jan; 130():106264. PubMed ID: 36395603
[TBL] [Abstract][Full Text] [Related]
8. In silico screening-based discovery of novel covalent inhibitors of the SARS-CoV-2 3CL protease.
Xiong M; Nie T; Shao Q; Li M; Su H; Xu Y
Eur J Med Chem; 2022 Mar; 231():114130. PubMed ID: 35114541
[TBL] [Abstract][Full Text] [Related]
9. Identification of Vitamin K3 and its analogues as covalent inhibitors of SARS-CoV-2 3CL
Wang R; Hu Q; Wang H; Zhu G; Wang M; Zhang Q; Zhao Y; Li C; Zhang Y; Ge G; Chen H; Chen L
Int J Biol Macromol; 2021 Jul; 183():182-192. PubMed ID: 33901557
[TBL] [Abstract][Full Text] [Related]
10. Potential of coronavirus 3C-like protease inhibitors for the development of new anti-SARS-CoV-2 drugs: Insights from structures of protease and inhibitors.
He J; Hu L; Huang X; Wang C; Zhang Z; Wang Y; Zhang D; Ye W
Int J Antimicrob Agents; 2020 Aug; 56(2):106055. PubMed ID: 32534187
[TBL] [Abstract][Full Text] [Related]
11. Structure-Based Optimization of ML300-Derived, Noncovalent Inhibitors Targeting the Severe Acute Respiratory Syndrome Coronavirus 3CL Protease (SARS-CoV-2 3CL
Han SH; Goins CM; Arya T; Shin WJ; Maw J; Hooper A; Sonawane DP; Porter MR; Bannister BE; Crouch RD; Lindsey AA; Lakatos G; Martinez SR; Alvarado J; Akers WS; Wang NS; Jung JU; Macdonald JD; Stauffer SR
J Med Chem; 2022 Feb; 65(4):2880-2904. PubMed ID: 34347470
[TBL] [Abstract][Full Text] [Related]
12. Flavonoids in Ampelopsis grossedentata as covalent inhibitors of SARS-CoV-2 3CL
Xiong Y; Zhu GH; Zhang YN; Hu Q; Wang HN; Yu HN; Qin XY; Guan XQ; Xiang YW; Tang H; Ge GB
Int J Biol Macromol; 2021 Sep; 187():976-987. PubMed ID: 34333006
[TBL] [Abstract][Full Text] [Related]
13. Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19.
Hoffman RL; Kania RS; Brothers MA; Davies JF; Ferre RA; Gajiwala KS; He M; Hogan RJ; Kozminski K; Li LY; Lockner JW; Lou J; Marra MT; Mitchell LJ; Murray BW; Nieman JA; Noell S; Planken SP; Rowe T; Ryan K; Smith GJ; Solowiej JE; Steppan CM; Taggart B
J Med Chem; 2020 Nov; 63(21):12725-12747. PubMed ID: 33054210
[TBL] [Abstract][Full Text] [Related]
14. Discovery, synthesis and mechanism study of 2,3,5-substituted [1,2,4]-thiadiazoles as covalent inhibitors targeting 3C-Like protease of SARS-CoV-2.
Ren P; Yu C; Zhang R; Nie T; Hu Q; Li H; Zhang X; Zhang X; Li S; Liu L; Dai W; Li J; Xu Y; Su H; Zhang L; Liu H; Bai F
Eur J Med Chem; 2023 Mar; 249():115129. PubMed ID: 36702052
[TBL] [Abstract][Full Text] [Related]
15. Repurposing of HIV/HCV protease inhibitors against SARS-CoV-2 3CL
Ma L; Li Q; Xie Y; Jianyuan Zhao ; Yi D; Guo S; Guo F; Wang J; Yang L; Cen S
Antiviral Res; 2022 Nov; 207():105419. PubMed ID: 36155070
[TBL] [Abstract][Full Text] [Related]
16. Discovery of novel SARS-CoV-2 3CL protease covalent inhibitors using deep learning-based screen.
Wang L; Yu Z; Wang S; Guo Z; Sun Q; Lai L
Eur J Med Chem; 2022 Dec; 244():114803. PubMed ID: 36209629
[TBL] [Abstract][Full Text] [Related]
17. Discovery of Covalent Lead Compounds Targeting 3CL Protease with a Lateral Interactions Spiking Neural Network.
Gu Z; Yan Y; Liu H; Wu D; Yao H; Lin K; Li X
J Chem Inf Model; 2024 Apr; 64(8):3047-3058. PubMed ID: 38520328
[TBL] [Abstract][Full Text] [Related]
18. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
Froggatt HM; Heaton BE; Heaton NS
J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
[TBL] [Abstract][Full Text] [Related]
19. Danshensu inhibits SARS-CoV-2 by targeting its main protease as a specific covalent inhibitor and discovery of bifunctional compounds eliciting antiviral and anti-inflammatory activity.
Wang R; Chen X; Li H; Chen X; Sun D; Yu D; Lu J; Xie Y; Zhang Q; Xu J; Zhang W; Chen H; Liu S; Chen L
Int J Biol Macromol; 2024 Feb; 257(Pt 2):128623. PubMed ID: 38070810
[TBL] [Abstract][Full Text] [Related]
20. Structure-guided design of direct-acting antivirals that exploit the gem-dimethyl effect and potently inhibit 3CL proteases of severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2) and middle east respiratory syndrome coronavirus (MERS-CoV).
Dampalla CS; Miller MJ; Kim Y; Zabiegala A; Nguyen HN; Madden TK; Thurman HA; Machen AJ; Cooper A; Liu L; Battaile KP; Lovell S; Chang KO; Groutas WC
Eur J Med Chem; 2023 Jun; 254():115376. PubMed ID: 37080108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
